References
  1. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. J Oral Maxillofac Surg 2014; 72:1938-1956.
  2. Hohnecker JA. DearDoctor. PrecautionsAddedto the LabelofAredia and Zometa. East Hanover, NJ, Novartis Oncology, 2004. p 2
  3. United States Food and Drug Administration, Office of Drug Safety: Postmarketing safety review. Bisphosphonates. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/20054095B2_03_04-FDA-Tab3.pdf. Accessed October 09, 2019
  4. Lipton A, Steger GG, Figueroa J, et al. Randomized activecontrolled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25:4431-4437.
  5. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132-5139.
  6. Malan J, Ettinger K, Naumann E, Beirne OR. The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:671-676.
  7. Owosho AA, Blanchard A, Levi L, et al. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: a series of thirteen patients. J Craniomaxillofac Surg 2016; 44:265-270.
  8. Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:e1-e3.
  9. Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26:4037-4038.
  10. Nicolatou-Galitis O, Migkou M, Psyrri A, et al. Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:234-238.
  11. Kim DW, Jung YS, Park HS, Jung HD. Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral Maxillofac Surg 2013;51:e302-e304.
  12. Owosho AA, Scordo M, Yom SK, et al. Osteonecrosis of the jaw a new complication related to Ipilimumab. Oral Oncol 2015;51: e100-e101.
  13. Ponzetti A, Pinta F, Spadi R, et al. Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Tumori 2016;102.
  14. Mawardi H, Enzinger P, McCleary N, et al. Osteonecrosis of the jaw associated with ziv-aflibercept. J Gastrointest Oncol 2016; 7:E81-E87.
  15. Nicolatou-Galitis O, Galiti D, Moschogianni M, et al. Osteonecrosis of the jaw in a patient with acute myeloid leukemia, who received azacitidine. J Cancer Metasta Treat. 2016;2:220-223.
  16. Nicolatou-Galitis O, Razis E, Galiti D, Vardas E, Tzerbos F, Labropoulos S. Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib: a case report with clinical implications. Forum Clin Oncol 2013;4:29-33.
  17. Owosho AA, Liang STY, Sax AZ, et al. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. Oral Surg Oral Med Oral Pathol Oral Radiol 2018;125:440–445
  18. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23.
  19. Kolokythas A, Olech E, Miloro M. Alveolar Osteitis: A Comprehensive Review of Concepts and Controversies. Int J Dent 2010;2010:249073.
  20. Taberner-Vallverdú M, Nazir M, Sánchez-Garcés MÁ, et al. Efficacy of different methods used for dry socket management: A systematic review. Med Oral Patol Oral Cir Bucal 2015;20(5):e633-9.
  21. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clinical Cancer Res: Off J Am Assoc Cancer Res 2012;18:2039–47.
  22. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304–9.
  23. Burki TK. Ipilimumab prolongs survival in advanced melanoma. Lancet Oncol 2016;17(11):e481
  24. Donia M, Fagone P, Nicoletti F, et al. BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 2012; 1(9):1476-1483.
  25. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010;70(13):5213-9.